Health campaigners call for greater checks on AbbVie/Allergan merger

Trade unions and consumer groups have urged the Federal Trade Commission (FTC) to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie, Taro settle over rosacea drug patents

27 May 2021 AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

Americas

AbbVie slammed over ‘drip feed’ of Imbruvica patents

20 July 2020 AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments

28 January 2020 Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.

More on this story

Americas

AbbVie, Taro settle over rosacea drug patents

27 May 2021 AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

Americas

AbbVie slammed over ‘drip feed’ of Imbruvica patents

20 July 2020 AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments

More on this story

Americas

AbbVie, Taro settle over rosacea drug patents

27 May 2021 AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

Americas

AbbVie slammed over ‘drip feed’ of Imbruvica patents

20 July 2020 AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica, a new report has revealed.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments